Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody...
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
About this item
Full title
Author / Creator
Hinterberger, Maria , Endt, Kathrin , Bathke, Barbara , Habjan, Matthias , Heiseke, Alexander , Schweneker, Marc , Von Rohrscheidt, Julia , Atay, Cigdem , Chaplin, Paul , Kalla, Markus , Hausmann, Jürgen , Schmittwolf, Carolin , Lauterbach, Henning , Volkmann, Ariane , Hochrein, Hubertus and Medina-Echeverz, José
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
The induction of antiviral innate immunity by systemic immunization with live virus can be employed to positively impact the response to therapeutic vaccination. We previously demonstrated that systemic immunization with a non-replicating MVA encoding CD40 ligand (CD40L) enhances innate immune cell activation and function, and triggers potent antit...
Alternative Titles
Full title
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_069aec9d569d4a3e88025d5a9a8e6ab5
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_069aec9d569d4a3e88025d5a9a8e6ab5
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-023-32060-2
